Mira Pharmaceuticals Inc. $(MIRA)$ has announced new results from an animal study involving SKNY-1, an oral therapeutic under definitive agreement for acquisition from SKNY Pharmaceuticals, Inc. The study, conducted using a zebrafish model that simulates human obesity and craving behaviors, demonstrated that SKNY-1 achieved significant outcomes within six days of treatment. Notably, SKNY-1 resulted in up to 30% weight loss while preserving muscle density, increased metabolic activity, and improved liver and lipid profiles. Additionally, SKNY-1 was found to reduce nicotine cravings and compulsive behaviors, as well as normalize neurohormonal imbalances associated with obesity. These findings support the advancement of SKNY-1 toward Investigational New Drug $(IND.AU)$-enabling studies, with Mira Pharmaceuticals prioritizing it as a potential cornerstone asset in light of the significant global market opportunity for obesity and smoking-related therapies.